Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC : a retrospective chart review (REFLECT)
/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.]]>
© The Author(s), 2021
2021
2021-12-15 14:29:41
1033
non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Europe, Central Europe, Eastern Europe
nedrobnocelični karcinom pljuč, imunoterapija, napredovali nedrobnocelinčni karcinom pljuč, podatki iz resničnega življenja, Evropa, srednja Evropa, Vzhodna Evropa
Sage
Alfredo
Addeo
70
Maximilian J
Hochmair
70
Urška
Janžič
70
Elizabeth
Dudnik
70
Andriani
Charpidou
70
Adam
Płużański
70
Tudor
Ciuleanu
70
Ivan
Shterev Donev
70
Judith
Elbaz
70
Jørgen
Aarøe
70
René
Ott
70
Nir
Peled
70
UDK
4
616-006
ISSN pri članku
9
1758-8359
DOI
15
10.1177/17588359211059874
COBISS_ID
3
89318403
0
Izvorni URL
2021-12-15 14:29:46